Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | KDM5C | P41229 | 1/20 | 0.57 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.57 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.57 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12213974 | 0.82 | KDM4E (0.43) | KDM4EKDM5CEGLN1PHF8KDM2A | |
| SCHEMBL2242250 | 0.80 | — | — | |
| SCHEMBL6773592 | 0.80 | — | — | |
| SCHEMBL12725535 | 0.80 | — | — | |
| SCHEMBL18576296 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL2227956 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL15414360 | 0.78 | — | — | |
| SCHEMBL16807522 | 0.78 | — | — | |
| SCHEMBL1750673 | 0.78 | — | — | |
| SCHEMBL6124941 | 0.78 | KDM4E (0.64) | KDM4EKDM5CEGLN1PHF8KDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021044884-A1 | CURABLE RESIN COMPOSITION, SEALING AGENT FOR LIQUID CRYSTAL DISPLAY ELEMENT, VERTICALLY CONDUCTIVE MATERIAL, AND LIQUID CRYSTAL DISPLAY ELEMENT | 積水化学工業株式会社 | 2021-03-11 | — | — | WO | disclosed |
| US-9156783-B2 | Compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150025042-A1 | Compounds For Treating Proliferative Disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20130338162-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-12-19 | — | — | US | disclosed |
| US-8609720-B2 | Compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8497272-B2 | Compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8383133-B2 | Conjugates of Plasmodium falciparum surface proteins as malaria vaccines | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110245262-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2011-10-06 | — | — | US | disclosed |
| US-20100183678-A1 | CONJUGATES OF PLASMODIUM FALCIPARUM SURFACE PROTEINS AS MALARIA VACCINES | The Govenment of the United States of America as represented by tge Secreatary of Health (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100081635-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2010-04-01 | — | — | US | disclosed |
| EP-2074097-A2 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | Synta Pharmaceuticals Corporation (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-2057117-A2 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | Synta Pharmaceuticals Corporation (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008024303-A2 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024302-A2 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081635-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | HSPB1, HSP90AB1, HSPA1B | KDM4E 3072/4885KDM5C 2631/4885EGLN1 4300/4885 |
| US-20110245262-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | HSP90AB1, HSF1, HSP90B1 | KDM4E 4105/4885KDM5C 3649/4885EGLN1 4564/4885 |
| US-20100183678-A1 | CONJUGATES OF PLASMODIUM FALCIPARUM SURFACE PROTEINS AS MALARIA VACCINES | CD4, RPS25, OSBP2 | KDM4E 4237/4885KDM5C 3071/4885EGLN1 2356/4885 |
| US-20150025042-A1 | Compounds For Treating Proliferative Disorders | HSP90AB1, HSPB1, HSP90AB2P | KDM4E 3309/4885KDM5C 3183/4885EGLN1 4500/4885 |
| US-20130338162-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | HSP90AB1, HSF1, HSP90B1 | KDM4E 4105/4885KDM5C 3649/4885EGLN1 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.